Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 6/20 | 0.68 |
| ▸ | F11 | P03951 | 5/20 | 0.68 |
| ▸ | TPSB2 | P20231 | 4/20 | 0.68 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.68 |
| ▸ | PLG | P00747 | 1/20 | 0.68 |
| ▸ | PLAU | P00749 | 1/20 | 0.68 |
| ▸ | F7 | P08709 | 1/20 | 0.68 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.65 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.65 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.65 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.65 |
| ▸ | HTR1A | P08908 | 1/20 | 0.61 |
| ▸ | DRD2 | P14416 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.54 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.54 |
| ▸ | FABP4 | P15090 | 1/20 | 0.54 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.54 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31757965 | 1.00 | CFD (0.68) | CFDF11TPSB2KLKB1PLG | |
| SCHEMBL5092502 | 0.90 | CFD (0.58) | CFDF11TPSB2KLKB1PLG | |
| SCHEMBL28900188 | 0.89 | PTGER1 (0.68) | CFDF11TPSB2KLKB1PLG | |
| SCHEMBL1412911 | 0.88 | HTR1A (0.59) | CFDF11TPSB2KLKB1PLG | |
| SCHEMBL10591847 | 0.87 | FABP4 (0.72) | CFDF11TPSB2KLKB1PLG | |
| SCHEMBL68571 | 0.86 | L3MBTL1 (0.69) | CFDF11TPSB2KLKB1PLG | |
| Methane SCHEMBL22289610 | 0.86 | HTR1A (0.57) | CFDF11TPSB2KLKB1PLG | |
| SCHEMBL1462035 | 0.86 | HTR1A (0.57) | CFDF11TPSB2KLKB1PLG | |
| SCHEMBL31757878 | 0.86 | HTR1A (0.57) | CFDF11TPSB2KLKB1PLG | |
| SCHEMBL17892024 | 0.86 | ABCB1 (0.66) | CFDF11TPSB2KLKB1PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2279732-A2 | Compounds and compositions for delivering active agents | Emisphere Technologies, Inc. (US) | 2011-02-02 | — | — | EP | claimed |
| JP-2007537301-A | — | — | 2007-12-20 | — | — | JP | claimed |
| CN-1964939-A | Compounds and compositions for delivering active agents | EMISPHERE TECH INC (US) | 2007-05-16 | — | — | CN | claimed |
| EP-1756039-A4 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECH INC (US) | 2007-05-02 | — | — | EP | claimed |
| EP-1756039-A2 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | Emisphere Technologies, Inc. (US) | 2007-02-28 | — | — | EP | claimed |
| WO-2005112633-A2 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2005-12-01 | — | — | WO | claimed |
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | claimed |
| US-20230339934-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2023-10-26 | — | — | US | disclosed |
| US-20230339934-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2023-10-26 | — | — | US | disclosed |
| CN-116585297-A | Application of sulfonamide derivative | 云南大学附属医院 | 2023-08-15 | — | — | CN | disclosed |
| US-20230227412-A1 | Substituted Benzimidazole Derivative And Use Thereof | CHENGDU FANXI BIOPHARMA CO., LTD. (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230227412-A1 | Substituted Benzimidazole Derivative And Use Thereof | CHENGDU FANXI BIOPHARMA CO., LTD. (CN) | 2023-07-20 | — | — | US | disclosed |
| EP-4186891-A1 | SUBSTITUTED BENZIMIDAZOLE DERIVATIVE AND USE THEREOF | Chengdu Fanxi Biopharma Co., Ltd. (CN) | 2023-05-31 | — | — | EP | disclosed |
| US-4761420-A | CARDIOVASCULAR DISORDERS | LABORATOIRES SYNTEX S.A. (FR) | 1988-08-02 | — | — | US | disclosed |
| EP-0249245-A2 | Antihypertensive dihydropyridine derivatives | LABORATOIRES SYNTEX S.A. (FR) | 1987-12-16 | — | — | EP | disclosed |
| US-4704399-A | THROMBOXANE A2 ANTAGONISTS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-11-03 | — | — | US | disclosed |
| EP-0145260-A2 | 1,3-Dioxan-4-ylalkenoic acids | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-06-19 | — | — | EP | disclosed |
| EP-0011279-B1 | PROCESS FOR THE PREPARATION OF AROMATICALLY SUBSTITUTED ACETIC ACIDS | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1982-05-05 | — | — | EP | disclosed |
| US-4268442-A | REACTING AN AROMATIC ALKEHYDE WITH A TRIHALOMETHANE AND AN ALKANETHIOL IN THE PRESENCE OF A BASE AND AN APROTIC SOLVENT | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1981-05-19 | — | — | US | disclosed |
| EP-0011279-A1 | Process for the preparation of aromatically substituted acetic acids | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1980-05-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339934-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | TRPV4, TRPV1, TRPV2 | CFD 3718/4885F11 4714/4885TPSB2 530/4885 |
| US-20230227412-A1 | Substituted Benzimidazole Derivative And Use Thereof | PPARD, PPARG, PPARA | CFD 3518/4885F11 4215/4885TPSB2 2827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.